Alimera Sciences, Inc. (ALIM) recently announced that it has entered into a definitive agreement with Minnesota-based biopharmaceutical company, ANI Pharmaceuticals, Inc. (ANIP) , wherein the latter has agreed to acquire Alimera.Shares of Alimera shot up 75.9% on Jun 24 following the news announcement, while ANIP shares rose 7.3%.Per the deal terms, Alimera is set to be acquired by ANIP for $5.50 per share in cash and its investors will be entitled to a contingent value right for up to $0.50 per share if ce ...

MILWAUKEE, June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals.Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.In the transaction, Alimera public shareholders will receive only $5.50 per share in cash at closing and one non-tradable contingent valu ...

Alimera Sciences (NASDAQ:ALIM) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ:ANIP).This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock. It also includes contingent rights of 50 cents per share. These are payable if certain revenue goals are met in 2026 and 2027.Investors in Alimera Sciences will note that this offer is a 75% premium to ALIM stock’s prior closing price. It’s also an 82% premiu ...

Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.ANI shares are roughly flat at writing.  Alimera Sciences stock valued at a 75% premiumCopy link to sectionANI Pharmaceuticals is willing to pay $5.50 in cash for each share of Alimera Sciences. It has als ...

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to ...

Core Points - Alimera Sciences, Inc. announced the approval of inducement awards for five non-executive employees as part of their hiring strategy [1][2] - The inducement awards consist of stock options allowing the purchase of 64,000 shares at an exercise price of $3.00 per share, which is the closing price on the grant date [2] - The awards will vest over four years, with 25% vesting on the one-year anniversary of employment and the remaining 75% vesting in equal installments over the next 36 months [2] Company Overview - Alimera Sciences is a global pharmaceutical company focused on retinal health and improving vision longevity [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (Stat ...

Financial Data and Key Metrics Changes - Consolidated global net revenue increased 70% year-over-year to $23 million in Q1 2024, driven by the acquisition of YUTIQ and growth in global end-user demand [9][18] - Adjusted EBITDA was $1.8 million in Q1 2024, compared to an adjusted EBITDA loss of $2.4 million in Q1 2023 [9][21] - Net loss was approximately $6.3 million in Q1 2024, compared to approximately $5 million in Q1 2023 [21] Business Line Data and Key Metrics Changes - U.S. net revenue increased 92% to approximately $14.6 million in Q1 2024, primarily due to the acquisition of YUTIQ [10][18] - International net revenue grew 42% to approximately $8.5 million in Q1 2024, driven by a 53% increase in end-user demand [12][19] Market Data and Key Metrics Changes - U.S. end-user demand for products was up 96% in Q1 2024, including the addition of YUTIQ, and 2% on a pro forma basis [10][18] - International total end-user demand increased 53% to 2,050 units compared to Q1 2023 [19] Company Strategy and Development Direction - The company aims to grow the utilization of ILUVIEN and YUTIQ in 2024 and beyond, with a focus on cross-selling opportunities [23] - The NICE guidance in the U.K. is expected to expand the potential user base for ILUVIEN, positively impacting utilization in the second half of 2024 [13][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $105 million in revenue and at least 20% adjusted EBITDA margins for the year [9][24] - The company anticipates revenue fluctuations due to seasonality, but remains optimistic about long-term growth prospects [10][21] Other Important Information - The company has increased its term loan agreement by $5 million to provide more operating flexibility [22] - The first patient has been randomized in a significant clinical trial evaluating treatment options for radiation retinopathy [16] Q&A Session Summary Question: Awareness of Product Indications - Management acknowledged that there is an awareness issue among physicians regarding the dual indications of their products and is implementing an education campaign [26][29] Question: Rebating Strategy - A non-clinical value program was implemented to provide value back to physician practices using ILUVIEN or YUTIQ more consistently, with expectations for a small impact in Q2 [30][31] Question: Financial Support for Protocol AL Trial - The company will contribute approximately $1.25 million over four to five years for the protocol AL trial [41] Question: Impact of NICE Recommendation - The NICE recommendation is expected to potentially double the market for available patients in the U.K., but the speed of adoption remains uncertain [45] Question: Sales and Marketing Expenses - The company expects sales and marketing expenses to normalize after one-time costs incurred in Q1 2024 [35][63] Question: Field Feedback on New Messaging - Initial feedback on the new messaging has been positive, with advocates recognizing the importance of early intervention [68]

Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -200%. A quarter ago, it was expected that this eye drug developer would post earnings of $0.02 per share when it actually produced a loss of $0.07, delivering a surprise of -450%.Over the last four quarters, the company ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports First Quarter 2024 Results · Net Revenue up 70% to $23 Million vs. Q1 2023 · Global End User Demand Up 23% vs. Q1 2023 · Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced fi ...